These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 38760016)

  • 1. Restored Cytokine-Producing Capacities of Mucosal-associated Invariant T Cells in Pediatric Cystic Fibrosis Patients Treated with Elexacaftor/Tezacaftor/Ivacaftor.
    Bardin E; Dietrich C; Attailia M; Ferroni A; Jamet A; Lezmi G; Sermet-Gaudelus I; Leite-de-Moraes M
    Am J Respir Crit Care Med; 2024 Jul; 210(2):243-245. PubMed ID: 38760016
    [No Abstract]   [Full Text] [Related]  

  • 2. Elexacaftor/Tezacaftor/Ivacaftor therapy in cystic fibrosis children previously CFSPID: Is it over-medicalization?
    Terlizzi V
    J Cyst Fibros; 2024 Mar; 23(2):366-367. PubMed ID: 37838487
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy of elexacaftor-tezacaftor-ivacaftor in portuguese adolescents and adults with cystic fibrosis carrying non-F508del variants.
    Pinto MO; Santos AS; Castanhinha S
    Pulmonology; 2024; 30(5):485-487. PubMed ID: 38614858
    [No Abstract]   [Full Text] [Related]  

  • 4. Reversal of cystic bronchiectasis with elexacaftor/tezacaftor/ivacaftor.
    Middleton PG; Simmonds NJ
    Eur Respir J; 2024 Sep; 64(3):. PubMed ID: 39326905
    [No Abstract]   [Full Text] [Related]  

  • 5. Depression Symptoms in Patients with Cystic Fibrosis Fluctuate at Baseline and Improve with Elexacaftor/Tezacaftor/Ivacaftor Therapy.
    Piehler L; Thalemann R; Lehmann C; Stahl M; Mall MA; Graeber SY
    Am J Respir Crit Care Med; 2024 Aug; 210(3):365-367. PubMed ID: 38843542
    [No Abstract]   [Full Text] [Related]  

  • 6. Elexacaftor/Tezacaftor/Ivacaftor Effectiveness in N1303K Variant in Adult People With Cystic Fibrosis.
    Gonçalves Martynychen Canan M; Souza Sokoloski C; Rossetti Severo C; Zahi Rached S; Abensur Athanazio R
    Arch Bronconeumol; 2024 Aug; 60(8):526-528. PubMed ID: 38714384
    [No Abstract]   [Full Text] [Related]  

  • 7. Medication utilization and lung function changes after initiation of treatment with elexacaftor/tezacaftor/ivacaftor.
    De Vuyst R; Kam CW; McKinzie CJ; Esther CR
    Pediatr Pulmonol; 2024 Jul; 59(7):2051-2054. PubMed ID: 38629427
    [No Abstract]   [Full Text] [Related]  

  • 8. Reply to Piehler
    Duff AJA; Lee TWR
    Am J Respir Crit Care Med; 2024 Aug; 210(3):367. PubMed ID: 38843537
    [No Abstract]   [Full Text] [Related]  

  • 9. Reply: Reversal of structural abnormalities with elexacaftor/tezacaftor/ivacaftor in adults with cystic fibrosis: the earlier you start, the better the outcome will be!
    Chassagnon G; Burgel PR
    Eur Respir J; 2024 Sep; 64(3):. PubMed ID: 39326907
    [No Abstract]   [Full Text] [Related]  

  • 10. Immunosuppressant management upon elexacaftor/tezacaftor/ivacaftor initiation in cystic fibrosis patients with prior liver transplant.
    Coman D; Vincent C; Huard G; Marleau D; Lavoie A; Hercun J
    J Cyst Fibros; 2024 May; 23(3):561-562. PubMed ID: 38000917
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical effectiveness of elexacaftor/tezacaftor/ivacaftor in a man with A559T and 3120+1G>CFTR variants.
    Mitchell E; Albon D
    Pediatr Pulmonol; 2024 Jul; 59(7):2009-2011. PubMed ID: 38607232
    [No Abstract]   [Full Text] [Related]  

  • 12. Patients eligible for modulator drugs: Data from cystic fibrosis registry of Turkey.
    Çobanoğlu N; Özçelik U; Çakır E; Şişmanlar Eyüboğlu T; Pekcan S; Cinel G; Yalçın E; Kiper N; Emiralioğlu N; Şen V; Şen HS; Ercan Ö; Çokuğraş H; Kılınç AA; Al Shadfan LM; Yazan H; Altıntaş DU; Karagöz D; Demir E; Kartal Öztürk G; Bingöl A; Başaran AE; Sapan N; Çekiç Ş; Çelebioğlu E; Aslan AT; Gürsoy TR; Tuğcu G; Özdemir A; Harmancı K; Yıldırım GK; Köse M; Hangül M; Tamay Z; Süleyman A; Yüksel H; Yılmaz Ö; Özcan G; Topal E; Can D; Korkmaz Ekren P; Çaltepe G; Kılıç M; Özdoğan Ş; Doğru D
    Pediatr Pulmonol; 2020 Sep; 55(9):2302-2306. PubMed ID: 32453906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated creatine phosphokinase and rhabdomyolysis associated with elexacaftor/tezacaftor/ivacaftor use in cystic fibrosis.
    McKinzie CJ; Kam CW; Jones MC; Gifford LB; Loughlin CE; Noah TL; Shenoy VK; Dellon EP
    Pediatr Pulmonol; 2024 Jun; 59(6):1795-1797. PubMed ID: 38517044
    [No Abstract]   [Full Text] [Related]  

  • 14. Elexacaftor/tezacaftor/ivacaftor's effects on cystic fibrosis infections are maintained, but not increased, after 3.5 years of treatment.
    Morgan SJ; Coulter E; Betts HL; Solomon GM; Clancy JP; Rowe SM; Nichols DP; Singh PK;
    J Clin Invest; 2024 Sep; 134(20):. PubMed ID: 39235967
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy of Elexacaftor-Tezacaftor-Ivacaftor on chronic rhinosinusitis in cystic fibrosis.
    Di Gioia S; Lucca F; Venditto L; Sandri G; Tommasi N; Cipolli M; Molteni G
    Am J Otolaryngol; 2024; 45(3):104236. PubMed ID: 38417261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triple Therapy for Cystic Fibrosis
    Barry PJ; Mall MA; Álvarez A; Colombo C; de Winter-de Groot KM; Fajac I; McBennett KA; McKone EF; Ramsey BW; Sutharsan S; Taylor-Cousar JL; Tullis E; Ahluwalia N; Jun LS; Moskowitz SM; Prieto-Centurion V; Tian S; Waltz D; Xuan F; Zhang Y; Rowe SM; Polineni D;
    N Engl J Med; 2021 Aug; 385(9):815-825. PubMed ID: 34437784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protocol for Successful Desensitization to Ivacaftor and Elexacaftor/Tezacaftor/Ivacaftor in a Delayed Hypersensitivity Reaction Confirmed by the Lymphocyte Transformation Test.
    Mir-Ihara P; De Las Vecillas L; Heredia R; Fiandor A; González-Muñoz M; Zamarrón E; Prados C; Cabañas R
    J Investig Allergol Clin Immunol; 2024 Jun; 34(3):211-213. PubMed ID: 37966860
    [No Abstract]   [Full Text] [Related]  

  • 18. Elexacaftor/tezacaftor/ivacaftor (Trikafta) for cystic fibrosis.
    Med Lett Drugs Ther; 2020 Jan; 62(1589):5-7. PubMed ID: 31999662
    [No Abstract]   [Full Text] [Related]  

  • 19. Case report of two adults with F508del/3849+10 kb C > T genotype regaining exocrine pancreatic function following treatment with elexacaftor/tezacaftor/ivacaftor.
    Stastna N; Pokojova E
    J Cyst Fibros; 2024 Jul; 23(4):744-745. PubMed ID: 38101988
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacokinetic Enhancement of Elexacaftor/Tezacaftor/Ivacaftor for Cystic Fibrosis: A Cost Reduction Strategy to Address Global Disparities in Access.
    Hong E; Zampoli M; Beringer PM
    Clin Pharmacol Ther; 2024 Jun; 115(6):1204-1207. PubMed ID: 38385853
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.